Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is prescribed to lower intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension. GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Iricryn, a prostaglandin analog, is used to manage conditions that involve elevated intraocular pressure. Primary open-angle glaucoma: reduces intraocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma.

Iricryn may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash growth - Eye irritation or foreign‑body sensation - Blurred vision - Darkening of the iris or peri‑ocular skin - Dry eye sensation

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis, iritis) - Allergic reactions such as swelling of the eyelids or conjunctiva - Sudden loss of vision - Paradoxical increase in intraocular pressure - Corneal edema or ulceration - Persistent eye pain

Before using Iricryn, consider the following safety measures. - Hypersensitivity: avoid if known allergy to bimatoprost or any excipient. - Ocular infection: assess and treat any active infection prior to initiation. - Corneal health: monitor patients with compromised corneas closely. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Systemic conditions: exercise caution in patients with asthma or severe cardiovascular disease. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Bimatoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Known hypersensitivity to bimatoprost or any formulation component. - Concurrent use with other prostaglandin analog eye drops, which can increase risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide) may have additive pressure‑lowering effect. - Topical ocular anesthetics can enhance ocular irritation. - Non‑steroidal anti‑inflammatory eye drops may alter drug absorption. - Use with caution in patients receiving ocular corticosteroids, as steroid response may affect pressure control.